Stock Track | EyePoint Pharmaceuticals Soars 5.49% as RBC Boosts Price Target Amid Clinical Progress

Stock Track

6 hours ago

EyePoint Pharmaceuticals (EYPT) shares are soaring 5.49% in Thursday's intraday trading session, fueled by a bullish analyst update and positive developments in the company's pipeline. The surge comes as investors react to a significant price target upgrade and encouraging progress in clinical trials.

RBC Capital Markets has raised its price target for EyePoint from $28 to $39, representing a substantial 39% increase. The firm maintained its Outperform rating on the stock, albeit with a speculative risk designation. This upgrade aligns with the broader analyst consensus, as FactSet data shows an average "buy" rating for EyePoint, with a mean price target of $35.33.

Adding to the positive sentiment, EyePoint recently released its Q3 earnings report, which highlighted advancements in its DURAVYU program for retinal diseases. The company's progress in clinical trials for this promising treatment appears to be bolstering investor confidence in EyePoint's future prospects. As the biotech firm continues to make strides in developing innovative therapies for eye disorders, market participants seem increasingly optimistic about its potential for growth and success in the competitive pharmaceutical landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1126033678"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126033678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126033678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 00:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126033678","market":"hk","top_or_hot":-1,"title":"Stock Track | EyePoint Pharmaceuticals Soars 5.49% as RBC Boosts Price Target Amid Clinical Progress","media":"Stock Track","content":"<p>EyePoint Pharmaceuticals (EYPT) shares are soaring 5.49% in Thursday's intraday trading session, fueled by a bullish analyst update and positive developments in the company's pipeline. The surge comes as investors react to a significant price target upgrade and encouraging progress in clinical trials.</p>\n\n<p>RBC Capital Markets has raised its price target for EyePoint from $28 to $39, representing a substantial 39% increase. The firm maintained its Outperform rating on the stock, albeit with a speculative risk designation. This upgrade aligns with the broader analyst consensus, as FactSet data shows an average \"buy\" rating for EyePoint, with a mean price target of $35.33.</p>\n\n<p>Adding to the positive sentiment, EyePoint recently released its Q3 earnings report, which highlighted advancements in its DURAVYU program for retinal diseases. The company's progress in clinical trials for this promising treatment appears to be bolstering investor confidence in EyePoint's future prospects. As the biotech firm continues to make strides in developing innovative therapies for eye disorders, market participants seem increasingly optimistic about its potential for growth and success in the competitive pharmaceutical landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | EyePoint Pharmaceuticals Soars 5.49% as RBC Boosts Price Target Amid Clinical Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | EyePoint Pharmaceuticals Soars 5.49% as RBC Boosts Price Target Amid Clinical Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 00:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EyePoint Pharmaceuticals (EYPT) shares are soaring 5.49% in Thursday's intraday trading session, fueled by a bullish analyst update and positive developments in the company's pipeline. The surge comes as investors react to a significant price target upgrade and encouraging progress in clinical trials.</p>\n\n<p>RBC Capital Markets has raised its price target for EyePoint from $28 to $39, representing a substantial 39% increase. The firm maintained its Outperform rating on the stock, albeit with a speculative risk designation. This upgrade aligns with the broader analyst consensus, as FactSet data shows an average \"buy\" rating for EyePoint, with a mean price target of $35.33.</p>\n\n<p>Adding to the positive sentiment, EyePoint recently released its Q3 earnings report, which highlighted advancements in its DURAVYU program for retinal diseases. The company's progress in clinical trials for this promising treatment appears to be bolstering investor confidence in EyePoint's future prospects. As the biotech firm continues to make strides in developing innovative therapies for eye disorders, market participants seem increasingly optimistic about its potential for growth and success in the competitive pharmaceutical landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EYPT","symbol_name":"EyePoint","start_time":0,"source_url":"","article_id":"1126033678","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126033678","pubTimestamp":1762445221,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"EyePoint Pharmaceuticals (EYPT) shares are soaring 5.49% in Thursday's intraday trading session, fueled by a bullish analyst update and positive developments in the company's pipeline. The surge...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EYPT":"EyePoint"},"translate_title":"个股追踪|EyePoint Pharmaceuticals飙升5.49%，加拿大皇家银行在临床进展中上调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1},"content_text":"EyePoint Pharmaceuticals (EYPT) shares are soaring 5.49% in Thursday's intraday trading session, fueled by a bullish analyst update and positive developments in the company's pipeline. The surge comes as investors react to a significant price target upgrade and encouraging progress in clinical trials.\nRBC Capital Markets has raised its price target for EyePoint from $28 to $39, representing a substantial 39% increase. The firm maintained its Outperform rating on the stock, albeit with a speculative risk designation. This upgrade aligns with the broader analyst consensus, as FactSet data shows an average \"buy\" rating for EyePoint, with a mean price target of $35.33.\nAdding to the positive sentiment, EyePoint recently released its Q3 earnings report, which highlighted advancements in its DURAVYU program for retinal diseases. The company's progress in clinical trials for this promising treatment appears to be bolstering investor confidence in EyePoint's future prospects. As the biotech firm continues to make strides in developing innovative therapies for eye disorders, market participants seem increasingly optimistic about its potential for growth and success in the competitive pharmaceutical landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}